FDA vs FDA: how a panel overruled the agency’s own scientists

This is the written version of FDA Committee Sided Against Their Scientists — Peptide Vote Outcome — watch it on the channel, or read on.

You have almost certainly seen the headline by now: “FDA approves peptides.” I want to open by saying that headline is wrong in basically every word. The FDA did not approve anything. Not BPC-157, not TB-500, not one of the seven compounds on the agenda.

What did happen is stranger, and honestly more interesting. Over two days, the FDA’s own advisory committee sat down with the work of the FDA’s own scientific reviewers — and told them they had got it wrong. On six of the seven.

I am a chartered chemical process engineer, which this week made me the man who reads two full days of government meeting transcripts so you do not have to. If you want the mechanics of what the 503A list even is and how a substance gets onto it, that is the pre-meeting write-up. This piece is about what was actually said in the room, and what it does and does not change.

Zero for seven, and then yes anyway

The committee is the Pharmacy Compounding Advisory Committee — PCAC. Over two days it reviewed seven peptides: BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon and DSIP. One question each time. Should this substance go on the 503A bulks list — the list of ingredients a compounding pharmacy is permitted to make to order against a prescription?

Here is the setup nobody puts in the headline. Before the meeting, FDA’s career scientists had done their homework and handed the panel a verdict: no. On all seven. Their assessment was that not one of the seven met a single one of the agency’s four tests — in plain terms: do we know what this substance actually is, is it safe, does it work, and has it been used this way before. Zero for seven.

And then the panel voted yes anyway. BPC-157, eight to six. TB-500, eight to six. KPV, the same. MOTS-c, Semax and Epitalon all recommended too. Six of the seven, with the committee overruling the agency’s own experts on nearly all of them.

Look at those margins, though. Nothing there was a landslide. This was a room that argued.

The one rejection that proves it wasn’t a rubber stamp

Nearly all — but not quite. There was exactly one the committee would not sign off on. DSIP, the sleep peptide, went down six to seven. Rejected.

That single no is the most useful data point of the whole meeting, because it tells you what kind of room this was. One pharmacist on the panel, David Pope, voted yes on every other peptide across two days — and voted no on this one. When even the reliable yes flips, the read is straightforward: the sleep data was simply too thin. The studies under review were characterised as preliminary and insufficient. The committee agreed with the agency exactly once, and this was it.

Which means the other six yes votes were not reflexive. People in that room were weighing each substance on its own evidence and landing in different places. So how does a room of physicians and pharmacists look at “no on all counts” and press yes?

“You’re grading this on the wrong exam”

The yes case came down to one argument, made several ways: the agency was marking this paper against the wrong syllabus. As one panel pharmacist, Bobby Harshburger, put it — “the 503A standards are not the same as a new drug approval standard.”

Nobody in that room claimed these are proven wonder drugs. Compounding is a different and much older lane: a licensed pharmacy preparing something for one specific patient against one prescription. A pain physician on the panel, Dr Christian, argued the agency was applying phase-one drug-trial criteria to something that never asked to be a new drug — and offered an analogy that stuck with me. It is the difference between refusing to let a kid anywhere near a Ferrari, and putting a qualified professional in the passenger seat. The peptides are being driven either way. The only live question is whether there is anyone competent in the car.

And that is the part that actually lands, because these compounds are already everywhere on the gray market. Dr Melissa Loski described a patient who brought in a vial labelled “research grade” to be checked. It came back laced with MDMA and ecstasy. Her verdict on the status quo: “that’s not protecting the American people.” Another speaker compressed the whole case into a single line — this is not a vote for or against peptides, it is a vote for or against safe access.

If you have ever squinted at a certificate of analysis wondering whether “HPLC 99%” actually means anything, that vial is the entire problem in one object. Working out what a lab report is really telling you is a skill, and it is the one thing in this story that is fully within your control.

The no votes were not cartoon villains

The other side had a real case, and you should hear it properly. Dr Bill Zamboni, a pharmacologist, said flatly that he was voting no because there is so little data he would have to work out how to even use these substances himself — which is not a position you want a prescriber to be in. For Epitalon specifically there was a genuine flag around telomerase activation, a possible cancer signal, and reviewers noted an absence of published efficacy data in the condition under review. That is exactly the sort of question that wants a long study, not a shrug.

Then the sharpest objection of the two days, from Dr Brian Lee: patients read “the FDA put it on a list” as “the FDA endorses it.” In his words, that endorsement “can be potentially harmful, and I cannot in good conscience vote yes.”

Hold onto that one, because it is precisely the trap the headline sets.

Three stages — and none of them is approval

So let us kill the trap. The vote does not make anything legal. Regulatory pipelines are weirdly my comfort zone, so here is the flow.

Stage one is the advisory committee — the vote that just happened. The clue is in the name. They recommend; they do not rule. It is a design review, not a building permit. Nobody has poured any concrete.

Stage two is rulemaking. The agency takes the recommendation, publishes a proposed rule, opens a public comment window that anyone can write into, and then — months later — issues a final rule. And the kicker: the FDA does not have to follow the vote. It usually does, and overruling a panel is rare, but until a final rule publishes, legally nothing has changed.

Stage three is the part worth tattooing on your forearm: even the final rule is not FDA approval. Being on the 503A list means a pharmacy is permitted to compound the substance. It does not mean the agency tested it and pronounced it safe and effective. Same molecule, completely different rulebook.

The guardrails nobody can actually require

One more wrinkle shows how early all of this is. A lot of those yes votes came with strings attached — panelists wanting US-only ingredients, patient registries, mandatory adverse-event reporting. All sensible. The problem is that the agency indicated it cannot require most of that through this particular pathway. So the guardrails that made several people comfortable voting yes are, for now, mostly aspiration.

And the twist: nobody was even asking

Here is the strangest part of the whole story, and it is not the vote. Every one of those seven peptides was originally nominated for the list by outside groups — and every single one of those nominations had been formally withdrawn before the meeting. The agency could simply have dropped the whole thing. Instead it picked the review back up and ran it anyway.

So: a two-day showdown, seven votes, an advisory committee publicly overruling its own agency’s scientists — over a question nobody was officially asking anymore.

The bottom line

A recommendation is not a permission slip.

What happened is genuinely a big deal, but it is the start of the paperwork, not the finish line. Nothing about what is legal to buy changed the following morning. And notice what none of it touched: not one word of that vote says any of these peptides is safe, effective, or right for anyone. Regulatory status and real evidence are two separate questions, and the loudest voices on both sides of this story have a commercial interest in you blurring them.

The panel itself was split down the middle on the underlying question, and I go back and forth on it too: if a compound is already all over the gray market, is a supervised, prescription-and-pharmacy version simply safer harm reduction — or does putting it on an FDA list hand it a credibility it has not earned? Both can be true at once, which is exactly why that room argued for two days.

Keep safe, keep skeptical.

Sources

1. FDA, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — meeting page, briefing materials and transcripts (primary source for vote tallies and panel quotes) — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
2. Regulatory Affairs Professionals Society (RAPS), FDA advisory committee backs controversial peptides over agency staff objections, July 2026 — https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
3. The Hill, FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists, July 2026 — https://thehill.com/homenews/5987510-fda-committee-votes-peptides/
4. Restore Health Consulting, FDA peptides meeting July 2026: what happens after the PCAC vote (advisory → proposed rule → public comment → final rule, 21 CFR §216.23) — https://www.restorehealthconsulting.com/news/fda-peptides-meeting-july-2026-what-happens-after-the-pcac-vote
5. Peptide Corner, Explained: FDA Peptide Vote — Ban or Legalise? (the pre-meeting explainer) — https://youtu.be/IkPa-XUScbU

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.